This day marks a turning point in their careers. The waiting, the interviews, the uncertainty — it all comes to a head here," ...

Suffolk, one of the largest and most innovative construction enterprises in the country, announced it hired Evan McKee as the ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Research led by The University of Texas Health Science Center at San Antonio identifies a means of blocking recurrence of glioblastoma, the deadliest brain cancer.

Childhood-onset striatonigral neurodegeneration robs children of the ability to walk and talk by age five. Researchers at ...

Clinical enrollment concludes for Spark Biomedical’s pivotal trial investigating a non-invasive, drug-free neurostimulation ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

DALLAS--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative construction enterprises in the country, announced it hired Evan McKee as the new Chief Operating Officer for the company ...

Suffolk grows Texas leadership team to support project diversification and continued regional expansion in high-growth sectors Suffolk, one of the largest and most innovative construction ...

Today, she owns Dallas-based Media Culture Inc., formerly Koeppel Direct, which specializes in direct-response marketing for ...

Researchers at The University of Texas Health Science Center at San Antonio have discovered a way to delay or even block ...